10-K/A: PetMed Express Restates Financials for Fiscal Years 2021-2023 Due to Sales Tax Errors

PetMed Express has restated its financial statements for fiscal years 2021 through 2023 due to accounting errors primarily related to sales tax liabilities.

Summary

• PetMed Express is filing an amendment to its annual report to restate previously issued financial statements for fiscal years 2021, 2022, and 2023.
• The restatement is due to errors in accounting for sales tax liabilities, which were not properly accrued.
• The company incorrectly applied U.S. GAAP related to sales tax liabilities, leading to material misstatements in prior financial statements.
• The restated sales tax accrual assumes all customers without exemption documentation are taxable and includes potential interest and penalties.
• The company also identified errors in the valuation of deferred taxes related to the acquisition of PetCareRx, which will be corrected in amended quarterly reports.
• The restatement resulted in a cumulative sales tax liability of $26 million as of March 31, 2023.
• The company's internal controls over financial reporting were deemed ineffective as of March 31, 2023, due to these material weaknesses.

Sentiment

Score: 3

Explanation: The document reveals significant accounting errors and material weaknesses in internal controls, leading to a restatement of financials. This is a negative development that raises concerns about the company's financial reporting and governance. The sentiment is further dampened by the delay in filing a quarterly report and the potential for litigation and regulatory action.

Positives

• The company is taking steps to correct the accounting errors and improve internal controls.
• The company is working with outside consultants to ensure proper application of U.S. GAAP.
• The company is implementing a remediation plan to address the identified material weaknesses.

Negatives

• The company's previously issued financial statements for fiscal years 2021, 2022, and 2023 should no longer be relied upon.
• The company identified material weaknesses in its internal control over financial reporting.
• The restatement resulted in a significant sales tax liability of $26 million as of March 31, 2023.
• The company's disclosure controls and procedures were not effective as of March 31, 2023.

Risks

• The company may face litigation or regulatory actions due to the restatement and material weaknesses.
• The company's inability to file a timely quarterly report has made it ineligible to file new short form registration statements on Form S-3 until March 2025.
• The company's stock price may be adversely affected by the restatement and material weaknesses.
• The company's failure to comply with various state or federal regulations may subject it to reprimands, sanctions, probations, fines, suspensions, or the loss of one or more of its pharmacy licenses.

Future Outlook

The company expects to make adjustments to the sales tax liability in future periods as and if it obtains any waivers of interest and penalties or other benefits from its voluntary disclosures and as and if it obtains additional documentation from customers supporting exemption from sales tax. The company anticipates advertising as a percentage of sales to be approximately 8.0% for fiscal year 2024 and general and administrative expense as a percentage of sales to approximate 17.0%, and expects stock compensation expense to approximate $6.4 million, in fiscal 2024.

Management Comments

• Management determined that we incorrectly applied U.S. GAAP as it relates to the sales tax liability included in our consolidated financial statements for each of the Affected Periods.
• Management has reassessed its evaluation of the effectiveness of its internal control over financial reporting as of March 31, 2023, and concluded that additional material weaknesses existed and that internal control over financial reporting and disclosure controls and procedures were not effective as of March 31, 2023.

Industry Context

The pet medication market is highly competitive, with veterinarians, online retailers, and traditional retailers all vying for market share. This restatement highlights the complexities of compliance with state and federal regulations in the online pharmacy sector.

Comparison to Industry Standards

• The restatement due to sales tax issues is not unique to PetMed Express, as many online retailers have faced similar challenges with the evolving landscape of state tax laws.
• The identification of material weaknesses in internal control over financial reporting is a concern, as it indicates potential issues with the company's financial processes, which is a key area of focus for investors and regulators.
• The company's response to the material weaknesses, including the implementation of a remediation plan, is consistent with industry best practices for addressing such issues.
• The company's focus on expanding its product offerings and strategic partnerships is a common strategy in the competitive pet medication market, as companies seek to diversify their revenue streams and customer base.

Management Changes

Related Party Transactions

• The Companys Board of Directors Chairman, Gian Fulgoni, serves on the board of directors of Prophet, a brand and marketing consulting company, which PetMed Express, Inc. engaged with in March 2021 for $292 thousand.

Stakeholder Impact

• Shareholders will be impacted by the restatement of financial statements and the identified material weaknesses.
• Employees may be impacted by changes in internal controls and processes.
• Customers may be impacted by any changes in the company's operations or services.
• Creditors may be impacted by the company's financial performance and any potential litigation or regulatory actions.

Next Steps

• The company will file amendments to the unaudited condensed consolidated quarterly financial information previously reported in its Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2023, and September 30, 2023.
• The company will restate the three and nine months ended December 31, 2022 to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023.
• The company will implement a remediation plan to address the identified material weaknesses in internal control over financial reporting.

Key Dates

Keywords

restatement, sales tax, internal control, financial reporting, material weakness, PetMed Express, accounting error, PetCareRx, GAAP, SEC